Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis
Background: Neoadjuvant chemotherapy has become the standard treatment for patients with locally advanced breast cancer. However, patients with hormone receptor positive (especially human epidermal growth receptor 2 negative) breast cancer show low response rate to neoadjuvant chemotherapy. Whether...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2023-04-01
|
| Series: | Clinical and Experimental Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/CEOG/50/4/10.31083/j.ceog5004074 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850260226756837376 |
|---|---|
| author | Zhen-Yu Li Ying-Li Dong Xiao-Zhong Cao Sha-Sha Ren Zhen Zhang |
| author_facet | Zhen-Yu Li Ying-Li Dong Xiao-Zhong Cao Sha-Sha Ren Zhen Zhang |
| author_sort | Zhen-Yu Li |
| collection | DOAJ |
| description | Background: Neoadjuvant chemotherapy has become the standard treatment for patients with locally advanced breast cancer. However, patients with hormone receptor positive (especially human epidermal growth receptor 2 negative) breast cancer show low response rate to neoadjuvant chemotherapy. Whether neoadjuvant chemo-endocrine therapy (NCET) can improve the pathological complete response (pCR) rate of these patients remains controversial. Methods: A systematic literature search was conducted in the PubMed, Embase, and Cochrane databases. Pooled odds ratio (OR) with 95% confidence intervals (CI) was calculated. Results: Five randomized controlled trials were included (N = 566). NCET did not significantly improve pCR (OR 1.35, 95% CI 0.77–2.38, p = 0.30). Conclusions: NCET did not to improve the pCR rates in patients with hormone receptor positive breast cancer. |
| format | Article |
| id | doaj-art-e149211eb6bb4752ad7d7200e7a42347 |
| institution | OA Journals |
| issn | 0390-6663 |
| language | English |
| publishDate | 2023-04-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Clinical and Experimental Obstetrics & Gynecology |
| spelling | doaj-art-e149211eb6bb4752ad7d7200e7a423472025-08-20T01:55:41ZengIMR PressClinical and Experimental Obstetrics & Gynecology0390-66632023-04-015047410.31083/j.ceog5004074S0390-6663(23)02029-8Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-AnalysisZhen-Yu Li0Ying-Li Dong1Xiao-Zhong Cao2Sha-Sha Ren3Zhen Zhang4Department of Breast Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, 471000 Luoyang, Henan, ChinaDepartment of Stomatology, Luoyang Central Hospital Affiliated to Zhengzhou University, 471000 Luoyang, Henan, ChinaDepartment of Breast Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, 471000 Luoyang, Henan, ChinaDepartment of Breast Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, 471000 Luoyang, Henan, ChinaDepartment of Breast Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, 471000 Luoyang, Henan, ChinaBackground: Neoadjuvant chemotherapy has become the standard treatment for patients with locally advanced breast cancer. However, patients with hormone receptor positive (especially human epidermal growth receptor 2 negative) breast cancer show low response rate to neoadjuvant chemotherapy. Whether neoadjuvant chemo-endocrine therapy (NCET) can improve the pathological complete response (pCR) rate of these patients remains controversial. Methods: A systematic literature search was conducted in the PubMed, Embase, and Cochrane databases. Pooled odds ratio (OR) with 95% confidence intervals (CI) was calculated. Results: Five randomized controlled trials were included (N = 566). NCET did not significantly improve pCR (OR 1.35, 95% CI 0.77–2.38, p = 0.30). Conclusions: NCET did not to improve the pCR rates in patients with hormone receptor positive breast cancer.https://www.imrpress.com/journal/CEOG/50/4/10.31083/j.ceog5004074breast cancerneoadjuvant chemotherapyneoadjuvant chemo-endocrine therapypathological complete response |
| spellingShingle | Zhen-Yu Li Ying-Li Dong Xiao-Zhong Cao Sha-Sha Ren Zhen Zhang Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis Clinical and Experimental Obstetrics & Gynecology breast cancer neoadjuvant chemotherapy neoadjuvant chemo-endocrine therapy pathological complete response |
| title | Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis |
| title_full | Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis |
| title_fullStr | Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis |
| title_full_unstemmed | Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis |
| title_short | Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis |
| title_sort | neoadjuvant chemo endocrine therapy for hormone receptor positive breast cancer a meta analysis |
| topic | breast cancer neoadjuvant chemotherapy neoadjuvant chemo-endocrine therapy pathological complete response |
| url | https://www.imrpress.com/journal/CEOG/50/4/10.31083/j.ceog5004074 |
| work_keys_str_mv | AT zhenyuli neoadjuvantchemoendocrinetherapyforhormonereceptorpositivebreastcancerametaanalysis AT yinglidong neoadjuvantchemoendocrinetherapyforhormonereceptorpositivebreastcancerametaanalysis AT xiaozhongcao neoadjuvantchemoendocrinetherapyforhormonereceptorpositivebreastcancerametaanalysis AT shasharen neoadjuvantchemoendocrinetherapyforhormonereceptorpositivebreastcancerametaanalysis AT zhenzhang neoadjuvantchemoendocrinetherapyforhormonereceptorpositivebreastcancerametaanalysis |